Reinsurance Group of America (RGA) Q4 2025 earnings review
Record Earnings and Raised Targets Defy Sector Volatility
RGA delivered a blowout Q4 to cap a record 2025, with Adjusted Operating EPS of $7.75 surging 55% YoY, significantly beating the prior year's $4.99. The company deployed a record $1.7 billion in capital for the year, driven by its 'Creation Re' strategy which pairs biometric risk with asset-intensive deals. Management projected high confidence by raising the intermediate-term ROE target to 13-15% and introducing a new 'Deployable Capital' metric of $1.7 billion. However, the outlook wasn't flawless: the earnings run-rate for U.S. Financial Solutions was lowered due to faster-than-expected annuity runoff, and biometric volatility remains a complex accounting headwind under LDTI.
🐂 Bull Case
The strategy of co-creating exclusive, asset-intensive deals is working. RGA deployed a record $1.7 billion in 2025 (+80% YoY), with over 50% of new business value now coming from these complex 'Creation Re' transactions rather than commoditized reinsurance.
High interest rates are a major earning driver. The Q4 new money rate was 6.04%, significantly above the portfolio yield of 4.83%. This spread ensures net investment income will continue to accelerate as the portfolio turns over.
🐻 Bear Case
Management lowered the forward earnings run-rate for the U.S. Financial Solutions segment. The runoff of older, high-margin annuity business is outpacing the earnings emergence from new Pension Risk Transfer (PRT) deals, which take 12-18 months to ramp up asset yields.
Despite favorable underlying claims for the full year, Q4 saw a $58 million unfavorable financial impact from biometric experience. LDTI accounting creates a disconnect where 'capped cohorts' force immediate recognition of negative volatility, while favorable variance is smoothed over years.
⚖️ Verdict: 🟢🟢
Strong Buy. RGA is executing flawlessly on its pivot to asset-intensive reinsurance. The raising of ROE targets to 13-15% suggests the Q4 beat is structural, not a fluke. While accounting noise persists, the economic fundamentals of the book are improving rapidly.
Key Themes
Asia Pacific Growth Explosion
Accelerating. Asia Pacific Traditional was a standout performer, with pre-tax adjusted operating income nearly doubling to $117M in 25Q4 from $63M a year ago. Management cited strong new business value in China and a landmark asset-intensive deal in Japan (~$200M initial reserve) driven by the region's shifting capital regimes (ESR).
Capital Metric Shift: 'Deployable Capital'
Management retired the point-in-time 'Excess Capital' metric in favor of 'Deployable Capital' ($1.7B), a forward-looking 12-month view. This metric includes projected capital generation and recognized value of in-force business. It signals aggressive intent to deploy capital into the pipeline rather than letting it sit or returning it solely via buybacks.
Biometric Volatility vs. Accounting
Q4 biometric experience was unfavorable by $52M on an underlying basis, translating to a $58M negative financial impact. While full-year underlying experience was favorable ($167M), LDTI accounting rules punish volatility in 'capped cohorts' immediately. This accounting mismatch obscures the true economic performance of the mortality book.
Asset Yield Arbitrage
Stable/Positive. The high-interest rate environment continues to boost RGA's spread-based businesses. The new money rate of 6.04% in Q4 remains well above the portfolio yield of 4.83%, creating a predictable earnings tailwind as the $100B+ investment portfolio slowly reprices.
Foreign Exchange Drag
A strengthening US Dollar reduced the Value of In-Force (VIF) by $1.1 billion in 2025. Management noted that using earlier 2025 FX rates would have resulted in an earnings run-rate $40-$50 million higher than the current guidance. This highlights a non-operational risk to the reported growth targets.
Balance Sheet Optimization
Accelerating. RGA isn't just writing new business; it's aggressively managing the back book. A Q4 recapture of 1999-2004 era treaties reduced risk and added value. In total, management actions added $2.1 billion to long-term value in 2025. A retro recapture announced earlier will ramp earnings by $20M in 2026, growing to $60M by 2040.
Other KPIs
Accelerating. Up 15% YoY, a sharp reversal from the full-year trend (down 3.4%). This was driven by strong contributions from single premium pension risk transfer (PRT) transactions ($200M vs $150M prior year) and organic growth in Traditional segments.
Accelerating. Up 47% YoY from $151M. Results benefited from in-force management actions and strong variable investment income, partially offset by expected unfavorable group claims experience.
Stable Growth. Up 8.8% YoY from $151.31 in 24Q4. This steady compounder metric underpins the raised ROE targets.
Guidance
Accelerating. Target raised from the previous 10-12% (and subsequent 12-14%) range. This reflects the structural improvement in earnings power from the 'Creation Re' strategy and higher interest rates.
Stable. Target reaffirmed, but now applied to a higher baseline run-rate following the record 2025 performance. Management assumes capital deployment of $1.5B-$2.0B annually to support this.
Decelerating. Slight tick up expected from the 22.9% realized in 2025FY and 22.8% in adjusted operating results.
Key Questions
U.S. Financial Solutions Growth Bridge
With the run-rate lowered due to annuity runoff, specifically how long will it take for the new PRT business (and its 12-18 month asset repositioning lag) to offset the decay and return the segment to net growth?
Biometric Volatility Accounting
Can you quantify the exact percentage of the traditional book that sits in 'capped cohorts' under LDTI? Understanding this exposure is critical to modeling quarterly volatility versus economic reality.
Deployable Capital vs. Buybacks
With $1.7B in deployable capital and a robust pipeline, buybacks are expected to be 'minimal.' At what point does the pipeline saturation trigger a return to significant share repurchases?